Navigation Links
Cephalon Reported Financial Results for the Second Quarter of 2011
Date:8/2/2011

FRAZER, Pa., Aug. 2, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported second quarter 2011 net sales of $730.1 million, a 2 percent increase compared to net sales of $712.4 million for the second quarter of 2010.  Basic income per common share for the period was $1.54 compared to $1.18 for the second quarter of 2010.  Excluding amortization expense and certain other items, adjusted net income for the second quarter of 2011 was $142.6 million, a 14 percent decrease versus the same period in 2010.  Basic adjusted income per common share for the quarter was $1.86, a 15 percent decrease from the $2.20 for the second quarter of 2010.  

Central nervous system (CNS) franchise net sales were $332.3 million during the quarter, a 5 percent decrease compared to the same period last year.  Pain franchise reported net sales of $140.6 million, a 4 percent increase versus second quarter 2010.  Oncology franchise net sales were $158.8 million, a 22 percent increase over the same period last year due to strong net sales of TREANDA® (bendamustine hydrochloride) of $125.8 million.  Sales of other products remained relatively constant at $98.5 million.

During the second quarter 2011 Cephalon recorded net cash provided by operating activities of $74.2 million and ended the period with $997.5 million of cash and cash equivalents.

"We continue to work with both US and European authorities to obtain all necessary regulatory approvals in order to close the transaction with Teva," said Kevin Buchi, Chief Executive Officer.

About Cephalon, Inc.Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 180 products in more than 100 countries. More information on Cephalon and its products is available at http://www.cephalon.com/.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding Teva's proposed acquisition of Cephalon; anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

This press release and/or the financial results attached to this press release include "Adjusted Net Income," "Basic Adjusted Income per Common Share," and "Diluted Adjusted Income Per Common Share," amounts that are considered "non-GAAP financial measures" under SEC rules. As required, we have provided reconciliations of these measures. Additional required information is located in the Form 8-K furnished to the SEC in connection with this press release.Contacts:Media:

Investors:Fritz Bittenbender

Robert (Chip) Merritt610-883-5855

610-738-6376fbittenb@cephalon.com

cmerritt@cephalon.comNatalie deVane

Joseph Marczely610-727-6536

610-883-5894ndevane@cephalon.com

jmarczely@cephalon.comCEPHALON, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share data)(Unaudited)Three Months EndedSix Months EndedJune 30,June 30,2011201020112010REVENUES:Net sales

$ 730,100$ 712,435$ 1,466,102$ 1,289,116Other revenues

8,16314,47517,27434,379738,263726,9101,483,3761,323,495COSTS AND EXPENSES:Cost of sales

123,667170,739281,650275,782Research and development

134,851101,261257,164206,638Selling, general and administrative

276,068258,468526,754463,109Change in fair value of contingent consideration

2,600-4,401-Restructuring charges

4,2794,5815,1375,325Acquired in-process research and development

--30,000-Impairment and (gain) loss on sale of assets

48,408-54,056-589,873535,0491,159,162950,854INCOME FROM OPERATIONS

148,390191,861324,214372,641OTHER INCOME (EXPENSE):Interest income

1,2531,3002,2703,230Interest expense

(24,475)(28,182)(48,682)(54,973)Change in fair value of investments

99,473-264,208-Other income (expense), net

(26,360)(9,332)(29,388)(16,603)49,891(36,214)188,408(68,346)INCOME BEFORE INCOME TAXES

198,281155,647512,622304,295INCOME TAX EXPENSE

83,08963,254185,820111,565NET INCOME

115,19292,393326,802192,730NET LOSS (INCOME) ATTRIBUTABLE TO NONCONTROLLING INTEREST

2,983(3,329)2,4616,899NET INCOME ATTRIBUTABLE TO CEPHALON, INC.

$ 118,175$   89,064$
329,263$
99,629BASIC INCOME PER COMMON SHARE ATTRIBUTABLE TO CEPHALON, INC.

$
.54$
.18$
4.32$
2.66DILUTED INCOME PER COMMON SHARE ATTRIBUTABLE TO CEPHALON, INC.

$
.34$
.11$
3.97$
2.46WEIGHTED AVERAGE NUMBER OF COMMONSHARES OUTSTANDING ATTRIBUTABLE TO CEPHALON, INC.

76,67975,19276,21375,092WEIGHTED AVERAGE NUMBER OF COMMONSHARES OUTSTANDING-ASSUMING DILUTIONATTRIBUTABLE TO CEPHALON, INC.

88,30380,50782,87181,223CEPHALON, INC. AND SUBSIDIARIESReconciliation of GAAP Net Income to Adjusted Net Income Attributable to Cephalon, Inc.(Unaudited)Three Months EndedJune 30,20112010GAAP NET INCOME ATTRIBUTABLE TO CEPHALON, INC.

$ 118,175$   89,064Cost of sales adjustments

(834)

(1)

52,209

(1)Research and development adjustments

320

(2)

317

(2)Selling, general and administrative adjustments

24,774

(3)

9,225

(3)Change in fair value of contingent consideration adjustment

2,600

(4)Restructuring adjustment

4,279

(5)

4,581

(5)Impairment and (gain) loss on sale of assets adjustment

48,408

(6)Interest expense adjustment

16,016

(7)

18,476

(7)Change in fair value of investments adjustment

(99,473)

(8)Other (income) expense adjustment

16,483

(9)

5,398

(9)Income tax adjustment

11,875

(10)

(14,017)

(10)*Noncontrolling Interest adjustments:Other revenues

--Research and development

1,214(2,018)Selling, general and administrative706200Interest income

--Interest expense

424(3)Other income (expense)

-1Income taxes

-(2,658)Less amount attributable to noncontrolling interest

(2,344)4,47824,44876,189ADJUSTED NET INCOME ATTRIBUTABLE TO CEPHALON, INC.

$ 142,623$ 165,253BASIC ADJUSTED INCOME PER COMMON SHARE

$
.86$
2.20DILUTED ADJUSTED INCOME PER COMMON SHARE

$
.62$
2.05WEIGHTED AVERAGE NUMBER OF COMMONSHARES OUTSTANDING

76,67975,192WEIGHTED AVERAGE NUMBER OF COMMONSHARES OUTSTANDING-ASSUMING DILUTION

88,30380,507* Amounts recorded by our Variable Interest Entities that have been excluded from net income attributable to Cephalon, Inc.Notes to Reconciliation of GAAP Net Income to Adjusted Net Income(1) To exclude the on-going amortization of acquired intangible assets ($26.9M in 2011: $32.2M in 2010), the reversal of a  royalty accrual related to AMRIX sales milestones that are no longer expected to be payable ($27.8M in 2011), accelerated depreciation related to restructuring ($5.5M in 2010), amortization of inventory revaluation related to Mepha ($5.0M in 2010) and the write-off of modafinil purchase commitments in excess of estimated requirements ($9.4M in 2010).(2) To exclude accelerated depreciation related to worldwide restructuring ($0.3M in 2011 and 2010).(3) In 2011, to exclude charges related to the unsolicited proposal we received from Valeant Pharmaceuticals International and the Agreement and Plan of Merger with Teva Pharmaceutical Industries Ltd. ($20.9M), and charges associated with recent acquisitions. In 2010, to exclude charges related to the acquisition of Mepha ($7.9M) and the acquisition of Ception noncontrolling interest ($1.4M). (4) In 2011, to exclude the change in fair value of the Ception Therapeutics, Inc. ($1.4M), BioAssets Development Company ($0.3M) and Gemin X Pharmaceuticals ($0.9M) contingent consideration.(5) To exclude costs related to restructurings.(6) In 2011, to exclude costs related to the impairments of AMRIX ($43.3M) and Mepha in-process research and development ($5.2M). (7) To exclude imputed interest expense associated with convertible debt.(8) In 2011, to exclude the change in fair value of our investments in Mesoblast Ltd. ($91.2M) and ChemGenex Pharmaceuticals Ltd. ($8.3M). (9) In 2011, to exclude costs and changes in fair value of certain derivative contracts ($16.5M).  In 2010, to exclude losses related to the acquisition of Mepha AG, including a loss on foreign exchange derivative instruments ($2.9M) and a loss on foreign exchange of Swiss Franc acquisition funds ($2.5M). (10) To reflect the tax effect of pre-tax adjustments at applicable tax rates and certain other tax adjustments primarily related to changes in valuation allowances and other changes in tax assets and liabilities.CEPHALON, INC. AND SUBSIDIARIESReconciliation of GAAP Net Income to Adjusted Net Income Attributable to Cephalon, Inc.(Unaudited)Six Months EndedJune 30,20112010GAAP NET INCOME ATTRIBUTABLE TO CEPHALON, INC.

$ 329,263$ 199,629Cost of sales adjustments

28,284

(1)

83,175

(1)Research and development adjustments

320

(2)

676

(2)Selling, general and administrative adjustments

25,704

(3)

11,502

(3)Change in fair value of contingent consideration adjustments

4,401

(4)

-Restructuring adjustment

5,137

(5)

5,325

(5)Acquired in-process research and development adjustments

30,000

(6)

-Impairment and (gain) loss on sale of assets adjustment

54,056

(7)

-Interest expense adjustment

31,691

(8)

36,055

(8)Change in fair value of investments adjustments

(264,208)

(9)

-Other (income) expense adjustment

16,989

(10)

11,567

(10)Income tax adjustment

39,359

(11)

(38,690)

(11)*Noncontrolling Interest adjustments:Other revenues

-(31)Research and development

1,4176,094Selling, general and administrative1,0633,222Other income (expense)

-166Interest income

-(7)Interest expense

723154Income taxes

-(3,848)Less amount attributable to noncontrolling interest

(3,203)(5,750)(28,267)109,610ADJUSTED NET INCOME ATTRIBUTABLE TO CEPHALON, INC.

$ 300,996$ 309,239BASIC ADJUSTED INCOME PER COMMON SHARE

$
3.95$
4.12DILUTED ADJUSTED INCOME PER COMMON SHARE

$
3.63$
3.81WEIGHTED AVERAGE NUMBER OF COMMONSHARES OUTSTANDING

76,21375,092WEIGHTED AVERAGE NUMBER OF COMMONSHARES OUTSTANDING-ASSUMING DILUTION

82,87181,223* Amounts recorded by our Variable Interest Entities that have been excluded from net income attributable to Cephalon, Inc.Notes to Reconciliation of GAAP Net Income to Adjusted Net Income(1) To exclude the on-going amortization of acquired intangible assets ($56.0M in 2011; $58.0M in 2010), the reversal of a royalty accrual related to AMRIX sales milestones that are no longer expected to be payable ($27.8M in 2011), accelerated depreciation related to restructuring ($10.7M in 2010), amortization of inventory revaluation related to Mepha ($5.0M in 2010) and the write-off of modafinil purchase commitments in excess of estimated requirements ($9.4M in 2010).(2) To exclude accelerated depreciation related to restructuring.(3) In 2011, to exclude charges related to the unsolicited proposal we received from Valeant Pharmaceuticals International and the Agreement and Plan of Merger with Teva Pharmaceutical Industries Ltd. ($20.9M), and charges associated with recent acquisitions.  In 2010, to exclude charges related to the acquisition of Mepha ($10.1M) and the acquisition of Ception noncontrolling interest ($1.4M). (4) In 2011, to exclude the change in fair value of the Ception Therapeutics, Inc. ($2.7M), BioAssets Development Company ($0.8M) and Gemin X Pharmaceuticals ($0.9M) contingent consideration.(5) To exclude costs related to restructurings.(6) In 2011, to exclude costs related to the acquisition of worldwide license rights to Mesoblast Limited's proprietary technology platform. (7) In 2011, to exclude costs related to the impairments of AMRIX ($43.3M) and Mepha in-process research and development ($5.2M) and costs associated with our plant to sell our manufacturing facility in Mitry Mory, France ($6.1M), offset by a gain on the sale of our facility in Savigny le Temple, France ($0.4M). (8) To exclude imputed interest expense associated with convertible debt.(9) In 2011, to exclude the change in fair value of our investments in Mesoblast Ltd. ($250.8M) and ChemGenex Pharmaceuticals Ltd. ($13.4M). (10) In 2011, to exclude costs and changes in fair value of certain derivative contracts ($17.0M).  In 2010, to exclude losses related to the acquisition of Mepha AG, including a loss on foreign exchange derivative instruments ($9.1M) and a loss on foreign exchange of Swiss Franc acquisition funds ($2.5M). (11) To reflect the tax effect of pre-tax adjustments at applicable tax rates and certain other tax adjustments primarily related to; changes in valuation allowances and other changes in tax assets and liabilities.CEPHALON, INC. AND SUBSIDIARIESCONSOLIDATED SALES DETAIL(In thousands)(Unaudited)Three Months Ended%June 30,Increase20112010(Decrease)United StatesEuropeTotalUnited StatesEuropeTotalUnited StatesEuropeTotalSales:CNSProprietary CNSPROVIGIL$
237,684$   13,462$
251,146$
268,550$   16,280$
284,830(11%)(17%)(12%)NUVIGIL58,576-58,57640,968-40,96843-43GABITRIL8,7651,1659,93011,1181,02412,142(21)14(18)Other Proprietary CNS-2,6082,608-2,6522,652-(2)(2)Generic CNS-9,9909,990-8,5748,574-1717CNS 305,02527,225332,250320,63628,530349,166(5)(5)(5)PainProprietary PainFENTORA41,9109,51651,42638,8615,66144,52286816Other Proprietary Pain----4949-(100)(100)Generic PainACTIQ14,60715,38729,99414,47114,06728,538195Generic OTFC6,015-6,01511,535-11,535(48)-(48)AMRIX13,554-13,55428,548-28,548(53)-(53)Generic AMRIX11,420-11,420---100-100Other Generic Pain-28,22428,224-21,55621,556-3131Pain87,50653,127140,63393,41541,333134,748(6)294OncologyProprietary OncologyTREANDA125,847-125,84799,732-99,73226-26Other Proprietary Oncology5,01721,69926,7166,25318,76925,022(20)167Generic Oncology-6,1886,188-5,7045,704-88Oncology130,86427,887158,751105,98524,473130,458231422OtherOther Proprietary4,7261,8046,5302,8831,7544,63764341Other Generic4,53687,40091,9363,05890,36893,42648(3)(2)Other9,26289,20498,4665,94192,12298,06356(3)0$
532,657$ 197,443$
730,100$
525,977$ 186,458$
712,4351%6%2%Six Months Ended%June 30,Increase20112010(Decrease)United StatesEuropeTotalUnited StatesEuropeTotalUnited StatesEuropeTotalSales:CNSProprietary CNSPROVIGIL$
481,027$   28,515$
509,542$
513,151$   34,130$
547,281(6%)(16%)(7%)NUVIGIL110,608-110,60875,890-75,89046-46GABITRIL19,8032,25422,05719,4172,48621,9032(9)1Other Proprietary CNS-4,9614,961-5,6585,658-(12)(12)Generic CNS-19,76519,765-10,88510,885-8282CNS 611,43855,495666,933608,45853,159661,617041PainProprietary PainFENTORA80,95316,87497,82777,3419,39086,73158013Other Proprietary Pain-6161-108108-(44)(44)Generic PainACTIQ30,09328,05658,14929,41132,55861,9692(14)(6)Generic OTFC15,038-15,03824,314-24,314(38)-(38)AMRIX36,586-36,58653,683-53,683(32)-(32)Generic AMRIX11,420-11,420---100-100Other Generic Pain-52,09052,090-23,69823,698-120120Pain174,09097,081271,171184,74965,754250,503(6)488OncologyProprietary OncologyTREANDA243,572-243,572180,989-180,98935-35Other Proprietary Oncology10,52041,43351,95310,80838,96049,768(3)64Generic Oncology-12,36612,366-9,8589,858-2525Oncology254,09253,799307,891191,79748,818240,615321028OtherOther Proprietary10,7314,01814,7498,2471,75410,0013012947Other Generic11,687193,671205,3587,154119,226126,380636262Other22,418197,689220,10715,401120,980136,381466361$
,062,038$ 404,064$ 1,466,102$
,000,405$ 288,711$ 1,289,1166%40%14%CEPHALON, INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS(In thousands, except share data)(Unaudited) June 30, December 31, 20112010CURRENT ASSETS:   Cash and cash equivalents

$
997,476$
,160,239   Receivables, net

486,519431,333   Inventory, net

305,421291,360   Deferred tax assets, net

206,895213,798   Other current assets

98,27254,845Total current assets

2,094,5832,151,575   INVESTMENTS ($505,800 and $155,808 at fair value in 2011 and 2010, respectively)

528,067168,494   PROPERTY AND EQUIPMENT, net

507,152502,856   GOODWILL

866,272822,071   INTANGIBLE ASSETS, net

1,724,2461,212,387   DEBT ISSUANCE COSTS

11,82914,196   OTHER ASSETS

20,93720,254$ 5,753,086$
4,891,833CURRENT LIABILITIES:   Current portion of long-term debt, net

$
72,102$
51,997   Accounts payable

120,128104,477   Accrued expenses

479,080460,141Total current liabilities

1,271,3101,216,615   LONG-TERM DEBT

405,985391,416   DEFERRED TAX LIABILITIES, net

237,487172,589   OTHER LIABILITIES

303,366273,438Total liabilities

2,218,1482,054,058REDEEMABLE EQUITY

153,600170,183EQUITY:Cephalon Stockholders' Equity   Common stock, $0.01 par value

813791   Additional paid-in capital

2,633,9132,428,450   Treasury stock, at cost

(225,881)(225,870)   Accumulated earnings

576,349247,086   Accumulated other comprehensive income

316,649182,975Total Cephalon stockholders' equity

3,301,8432,633,432Noncontrolling Interest

79,49534,160Total equity

3,381,3382,667,592$ 5,753,086$
4,891,833CEPHALON, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited)Six Months Ended June 30,20112010CASH FLOWS FROM OPERATING ACTIVITIES:Net income

$  326,802$  192,730Adjustments to reconcile net income to net cash provided by operating activities:Deferred income tax expense (benefit)

52,156(18,059)Shortfall tax benefits from stock-based compensation

(331)(559)Depreciation and amortization

93,389106,724Stock-based compensation expense

16,95021,630Amortization of debt discount and debt issuance costs

32,77635,692Changes in fair value of investments

(264,208)-Loss (gain) on foreign exchange contracts

(5,089)9,499Impairment and loss (gain) on sale of fixed assets

54,056-Other

23,0903,752Changes in operating assets and liabilities:Receivables

(37,532)(25,581)Inventory

5,64618,985Other assets

1,2079,474Accounts payable, accrued expenses and deferred revenues

(11,445)23,955Other liabilities

(65,462)(189)Net cash provided by operating activities

222,005378,053CASH FLOWS FROM INVESTING ACTIVITIES:Purchases of property and equipment

(28,049)(22,997)Proceeds from sale of property and equipment

818-Cash balance from consolidation of variable interest entity

15,513-Acquisition of Mepha net of cash acquired (549,463)Acquisition of Gemin X, net of cash acquired

(184,198)Acquisition of ChemGenex, net of cash acquired

(179,931)Purchases of investments

(135,453)(60)(Cash settlements of) proceeds from foreign exchange contracts

7,111(9,499)Net cash used for investing activities

(504,189)(582,019)CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from sale of common stock

349-Proceeds from exercises of common stock options

133,70314,370Windfall tax benefits from stock-based compensation

12,060-Acquisition of Ception non-controlling interest

-(299,289)Acquisition of ChemGenex Ltd. non-controlling interest

(6,602)Acquisition of treasury stock

-(33)Payments on and retirements of long-term debt

(35,763)(221,478)Net cash provided by (used for) financing activities

103,747(506,430)EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS

15,674(9,793)NET INCREASE IN CASH AND CASH EQUIVALENTS

(162,763)(720,189)CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD

1,160,2391,647,635CASH AND CASH EQUIVALENTS, END OF PERIOD

$  997,476$  927,446
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. Cephalon Quarterly Conference Call Invitation
2. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
3. $425 Million Cephalon Civil Settlement and Criminal Fine; In Americas Largest
4. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
5. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
6. Cephalon Reports Another Strong Quarter
7. Cephalon, Inc. to Webcast Analyst Day
8. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
9. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
10. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
11. Cephalons New Product Launches Pace Record 2008 Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... LEXINGTON, Massachusetts , February 9, 2016 ... Enables Children to Take Part in Life-Changing Camp ... announcing a new initiative designed to positively affect the lives of ... rare disease care. --> SHPG ) is announcing a ... with rare diseases, as well as the future of rare disease ...
(Date:2/8/2016)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... clean technology companies in the TSX Venture 50 TM . ... on the TSX Venture Exchange, in each of five major ... & life sciences, diversified industries and technology – based ... on investment, market cap growth, trading volume and analyst coverage. ...
(Date:2/8/2016)... February 8, 2016 ... Limited, an innovation-driven oncology company developing next generation ... toxic, today announced that chairman emeritus of Tata ... in the company as part of the first ... existing investors Navam Capital and Aarin Capital. ...
(Date:2/8/2016)...  BioElectronics Corporation (OTC Pink: BIEL), the maker ... it is responding to a notice of an ... Exchange Commission posted on the agency website.  ... Board of BioElectronics Corporation and the Edward and ... Fuqua School of Business, Duke University.   ...
Breaking Biology Technology:
(Date:2/2/2016)... --Technology Enhancements Accelerate Growth of X-ray Imaging This ... computed radiography markets in Thailand , ... (TIM). It provides an in-depth analysis of ... regional market drivers and restraints. The study offers revenue ... attractiveness, both for digital and computed radiography. Market participants ...
(Date:2/1/2016)... smart wallet ( www.wocketwallet.com ) announces the launch of a new video ... Las Vegas , where Joey appeared at the Wocket ... Vegas , where Joey appeared at the Wocket booth to meet ... filmed at the Consumer Electronics Show (CES2016) in Las Vegas ... greet fans. --> --> The ...
(Date:1/22/2016)... DUBLIN , January 22, 2016 ... has announced the addition of the  ... to their offering. --> ... of the  "Global Behavioral Biometric Market ... --> Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ...
Breaking Biology News(10 mins):